UN agency warns of ‘sharp increase’ in measles cases in the Americas

PAHO has issued an epidemiological alert after a sharp rise in measles across the Americas, documenting 1,031 cases in the first three weeks of 2026 and 14,891 confirmed cases in 2025. Major outbreaks are concentrated in North America: the US reported 2,242 cases in 2025 (171 early-2026 cases), including 876 cases in South Carolina (800 unvaccinated), and Texas saw 762 cases with two child fatalities and 99 hospitalisations; Mexico reported 6,428 cases in 2025 plus 740 in early 2026, while Canada lost elimination status after 5,436 cases in 2025. PAHO warned member states to strengthen surveillance and vaccination and will review US and Mexico elimination status on April 13, a development that could drive short-term policy responses, vaccine demand and localized healthcare strain.

Analysis

Market structure: Short-term winners are incumbent vaccine manufacturers (Merck/MRK), diagnostics (LabCorp/LH, Quest/DGX) and fill-finish/CMO providers (Catalent/CTLT) as governments accelerate catch-up campaigns; losers are travel/leisure names with concentrated Mexico/US exposure and local municipal budgets that may reallocate to public health. Public procurement is relatively inelastic and concentrated (federal/state buys), so incumbents with existing MMR capacity can win large, lumpy orders within 3–12 months, creating near-term pricing power for manufacturing services.

Risk assessment: Tail risks include political/regulatory shifts (e.g., litigation or vaccine-price controls) and supply-chain bottlenecks at sterile fill-finish that could delay deliveries 3–9 months; low-probability epidemiological shifts (vaccine-escape mutation) are very unlikely. Immediate effects (0–3 months) will be testing volume spikes and hospital utilization; procurement and budgetary cycles play out in 3–12 months; structural policy responses (mandates, school-entry rules) will materialize over 12–36 months and are the primary driver of sustained demand.

Trade implications: Direct tactical longs: MRK and CTLT for procurement & capacity leverage; LH/DGX for testing volume. Pair trades: long MRK/CTLT vs short travel/leisure names with Mexico exposure to hedge macro FX/MXN risk. Use calendar and vertical call spreads to express upside while capping premium; scale 50% now and add into weakness ahead of the PAHO review on Apr 13, 2026.

Contrarian angles: Markets may underprice a multi-year rebuild in pediatric immunization programs — beneficiaries include CMOs and public-health-focused pharma — while overreacting to short-term travel demand fears. Historical measles spikes produced localized but not sustained buy cycles; this time political anti-vax dynamics plus ~15k cases in 2025 make a sustained, multi-year procurement cycle plausible, but cap exposure to regulatory downside (size positions modestly).

Key Decisions for Investors

• Establish a 1.5% portfolio long position in Merck (MRK) to capture likely MMR procurement orders; overlay a 6–9 month call vertical (buy 1% OTM call, sell 10% OTM call) to cap premium; target 20–40% upside in 6–12 months, stop-loss at -12%.
• Initiate 1% each long positions in LabCorp (LH) and Quest Diagnostics (DGX) to capture testing/hospitalization volume; alternatively buy 3-month at-the-money calls sized to 0.5% portfolio if implied volatility < historical 90-day average; take profits at +25% or re-evaluate after Apr 13, 2026.
• Buy 1% long of Catalent (CTLT) to play fill-finish capacity tightness; if CTLT rallies >15% before new orders are announced, trim half. Pair this with a 1% short exposure to a Mexico-leisure/consolidated tourism name or EWW to hedge FX/consumer demand risk.
• If PAHO or CDC announcements on/around Apr 13, 2026 revoke elimination status or announce federal catch-up programs, add +1% to MRK and +0.5% to CTLT within 7 trading days; if no policy action by Apr 30, reduce new buys by 50%.
• Construct protective hedges: buy 3-month put spreads on high-exposure travel names (e.g., RCL) sized to 0.5–1% portfolio to insulate against short-term demand shocks; sell into volatility spikes >50% implied move.